• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 6/18/24: Honey’s Antibacterial Power, OpenAI's Healthcare Push & more


The latest news for pharma industry insiders.

The Argument for Data Alignment and Integration in Clinical Supply Management

Siloed systems can make it difficult to marry data to support timely and informed decision-making and optimize clinical trial operations.

New Study Reveals Fresh Honey’s Antibacterial Power Against Respiratory Pathogens

A new study published May 2024 in Scientific Reports examined the changes in morphology and antibacterial activity in four honey varieties from Hungary matched against respiratory pathogens.

Finding the Right Partner for Your Clinical Trial

Learn more about why CROs are advocating for operational shifts necessary to support the adoption of innovative solutions to capture data and the significance of partnering with a CRO who can support initiatives throughout the entire clinical trial continuum using innovative data capture methods and their knowledge to facilitate global submissions.

OpenAI Expands Healthcare Push With Color Health’s Cancer Copilot

Color Health has developed an AI assistant using OpenAI’s GPT-4o model to help doctors screen and treat cancer patients.

Attention Deficit Hyperactivity Disorder (ADHD) Opportunity Assessment and Forecasts 2022-2024 & 2032

The "Attention Deficit Hyperactivity Disorder (ADHD): Opportunity Assessment and Forecast 2022-2032" report has been added to ResearchAndMarkets.com's offering.

The ADHD therapeutics market, valued at $11.9 billion in the 2022 baseline year, is expected to encounter a negative compound annual growth rate (CAGR) of 0.9%, ultimately reaching an estimated $10.9 billion by 2032.

Fitzsimons Innovation Community on LinkedIn

A behind-the-scenes preview!

Thanks to Mike Hennessy, President & CEO of MJH Life Sciences® (publisher of Pharmaceutical Executive) for the great conversations at BIO 2024 with two leaders from our community member companies --GelSana Founder & CEO,Melissa Krebs, Ph.D., and OncoVerity CEO, Max Colao. We look forward to sharing the full interview soon!

#FitzCommunityMember #ColoradoBioBuzz #LifeSciences

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs